2023 Fiscal Year Final Research Report
Development of markers of childhood thyroid cancer recurrence using ctDNA in blood.
| Project/Area Number |
21K08600
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 55010:General surgery and pediatric surgery-related
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
岩舘 学 福島県立医科大学, 医学部, 講師 (00381393)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | thyroid / endocrinology |
|---|
| Outline of Final Research Achievements |
The results of genome profiling studies in thyroid cancer suggest that genetic abnormalities such as activation of PIK3CA, deletion of tumour suppressor genes (p16 p53) and TERT promoter mutations are associated with differentiation and growth of thyroid cancer, abnormal activation of the RdRP-mediated pathway of TERT, phosphorylation of It was suggested that multifaceted abnormalities such as increased expression and altered localisation of TERT in cancer cells may be associated with thyroid cancer grade, recurrence and prognosis.
|
| Free Research Field |
内分泌学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究では、がん関連遺伝子に着目し、がん関連タンパク発現量の定量化・プロモータ変異の解析、術前の血液に含まれるエクソソーム中のDNAのゲノム解析を行い、甲状腺がんの遺伝子変異を評価し、遺伝子変異、臨床データとがんの悪性度、予後との関連を後方視的に解析を行った。本研究成果から、従来の評価では悪性度の評価が困難である微小がんや侵襲性のがんに対し、術前の遺伝子診断を踏まえての治療方針決定を行えるという臨床応用の可能性が期待される。
|
